Huntington’s Disease Treatment Market Size, Share, Report 2023-2032
The global huntington’s disease treatment market size was estimated at around USD 0.42 billion in 2022 and it is projected to hit around USD 3.39 billion by 2032, growing at a CAGR of 23.23% from 2023 to 2032. The huntington’s disease treatment market in the United States was accounted for USD 3.7 billion in 2022.
Key Pointers
Report Scope of the Huntington’s Disease Treatment Market
| Report Coverage | Details |
| Revenue Share of North America in 2022 | 41% |
| Revenue Forecast by 2032 | USD 3.39 billion |
| Growth Rate from 2023 to 2032 | CAGR of 23.23% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Companies Covered | H. Lundbeck A/S; Teva Pharmaceutical Industries Ltd.; Bausch Health Companies Inc.; Hetero; Lupin; Hikma Pharmaceuticals PLC; Dr. Reddy’s Laboratories Ltd.; Sun Pharmaceutical Industries Ltd. |
The expected label expansion of Ingrezza for treating chorea associated with Huntington’s Disease (HD), high burden of HD in western countries, and strong product pipeline of disease-modifying therapies are anticipated to be major drivers for the market. HD roughly affects 30,000 people in North America, with a prevalence of 5.7 per 100,000 people. HD in children is considerably rarer, accounting for about 5% to 10% of all cases. It affects up to 10 out of 100,000 people in Europe.
HD is a progressive neurological condition caused by CAG expansions in the Huntingtin (Htt) gene. It affects one out of every 10,000 people in the U.S. Healthy people have less than 35 CAG repetitions, whereas HD patients have CAG expansions ranging from 36 to 200. The prevalence varies by more than ten-fold between geographical locations, which can be related to case ascertainment and diagnostic criteria variations. The Asian population has consistently had a lower prevalence, while Europe, North America, and Australia have a higher prevalence. Several small molecules in clinical development are focused on using immunomodulatory drugs to target the overactive immune system in HD.
Key players such as Annexon, Inc. is engaged in the development of ANX005-an experimental monoclonal antibody that targets abnormal C1q activity in complement-mediated neurodegenerative diseases, such as HD. This innovative medication is administered intravenously (IV) and is meant to suppress C1q and the complete classical complement system. In November 2020, the company initiated a phase 2 clinical trial of ANX005 for treating HD patients. Stem cell therapy is also generating interest as a potential treatment for HD. Currently, Cellavita, in collaboration with AzidusPharma, is investigating stem cell therapy, CELLAVITA-HD in phase 2/ 3 ADORE-DH trial.
However, drug development for HD has faced significant obstacles as several therapies have failed to demonstrate efficacy or were associated with significant toxicity. In March 2021, F. Hoffmann-La Roche Ltd. discontinued the dosing in the phase III GENERATION HD1 study of tominersen in manifest HD. The conclusion was made on the basis of findings of an unblinded Independent Data Monitoring Committee’s (iDMC) preplanned examination of data from the phase III research. During analysis of this data, no new or developing safety signals for tominersen were discovered. COVID-19 pandemic has had a slight negative impact on the market for Huntington’s disease treatment. However, the delays in conducting clinical trials due to the pandemic can delay the entry of pipeline candidates into the market.
Treatment Insights
The symptomatic treatment segment held the largest revenue share of 101% in 2022 and is expected to dominate HD treatment market over the forecast period. This growth is due to the availability of symptom management products and patent protection for these products. Xenazine and Austedo are considered first-line therapy for chorea associated with Huntington’s disease. The R&D of potential product candidates for symptom management of Huntington’s disease may contribute to segment growth. In October 2021, the U.S. FDA granted orphan drug designation to SOM BIOTECH’s drug SOM3355 for the treatment of chorea associated with Huntington’s disease. As a result, the product will have exclusivity for 7 years upon U.S. FDA approval.
The disease-modifying therapies segment is anticipated to witness the fastest growth over the forecast period. This is owing to an increase in R&D for disease-modifying therapy coupled with a rise in the demand for advanced products, such as gene therapy and stem cell therapy. The favorable government initiatives such as Fast Track Designation by the U.S. FDA for accelerating the registration process may fuel the market in the coming years. For instance, in September 2021, U.S. FDA granted fast track designation to Sage Therapeutics’s drug, SAGE-718, as a potential treatment for Huntington’s Disease.
End User Insights
The hospital pharmacy segment dominated the market in 2022 with a revenue share of over 58%. This dominance can be attributed to their comprehensive healthcare infrastructure, multidisciplinary approach to treatment, expertise in managing complex medications, access to a broad patient population, established relationships with pharmaceutical stakeholders, and commitment to quality care. Hospitals serve as primary healthcare providers for patients with complex conditions like Huntington's disease, and their pharmacies ensure the availability and distribution of specialized medications. With a multidisciplinary team of experts and a focus on patient care, hospital pharmacies have established themselves as key stakeholders in effectively managing and treating Huntington's disease.
The e-commerce segment is expected to expand at a lucrative CAGR over the forecast period. An increase in the usage of the internet and smartphone, ease of ordering medications through an e-commerce platform, and increasing e-commerce services globally are expected to fuel the segment growth in the coming years.
Regional Insights
North America held the largest revenue share of 41% in Huntington’s disease treatment market in 2022. This growth is due to the high burden of the disease, increased healthcare expenditure, technological advancements, proactive government initiatives, and increased patient awareness about treatment products for Huntington’s disease. Major players such as H. Lundbeck A/S and Teva Pharmaceutical Industries Ltd. support market growth by introducing symptom management products.
In Asia Pacific, the market for Huntington’s disease treatment is expected to witness significant CAGR over the forecast period due to increased product penetration, untapped potential, and the growing prevalence of the disease in developing countries over the forecast period. A rising number of initiatives being undertaken by governments to improve the health status of the population is expected to drive the growth of the market in the region. However, the market for Huntington’s disease treatment is competitive, which may hamper its growth in this region. For instance, in July 2021, Teva Pharmaceutical Industries Ltd. filed a patent lawsuit against Indian generic manufacturers Lupin Ltd. and Aurobind.
Huntington’s Disease Treatment Market Segmentations:
By Treatment
By End Use
By Regional
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers